Unlocking future medicines: The crucial role of clinical trials
Regeneron’s clinical trials are at the core of this mission. Regeneron is grateful to all clinical trial participants — ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup
Citigroup upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a hold rating in a research note ...
Final Trades: Berkshire Hathaway, Regeneron, DocuSign and Leidos Holdings
Dallas salon owner Shelley Luther discusses her comeback after being jailed for keeping her small business open during COVID ...
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
Check Out What Whales Are Doing With REGN
Looking at options history for Regeneron Pharmaceuticals REGN we detected 8 trades. If we consider the specifics of each ...
Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...
2 Top Growth Stocks to Buy on the Dip
Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...
Wolfe Research starts Regeneron at Outperform, sees ‘attractive entry point’
Wolfe Research initiated coverage of Regeneron (REGN) with an Outperform rating and $1,150 price target Eylea patent litigation concerns had ...
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
MarketWatch10d
Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market
Shares of Regeneron Pharmaceuticals Inc. REGN inched 0.07% higher to $829.43 Tuesday, on what proved to be an all-around ...
Morningstar3d
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
The latest research advances demonstrate the potential of Regeneron’s diverse pipeline, which aims to address unmet needs in ten types of blood cancers and disorders. These innovative and ...